2024-10-22 - Analysis Report
## Amgen Inc. (AMGN) Stock Analysis Report

This report provides a comprehensive analysis of Amgen Inc. (AMGN) stock, encompassing its performance against the S&P 500, recent price trends, technical indicators, latest earnings, news, and overall outlook.

**1. Performance Comparison with S&P 500 (VOO)**

Amgen Inc. (AMGN) has underperformed the S&P 500 (VOO) over the given period. The cumulative return for AMGN is 76.54%, while the S&P 500 has achieved 136.39%, resulting in a cumulative return difference of -59.85%. This places AMGN at the 26.31% percentile within its historical range of performance relative to the S&P 500.

**2. Recent Price Trends**

* **Current Price:** $315.68
* **5-day Moving Average:** $319.41
* **20-day Moving Average:** $320.64
* **60-day Moving Average:** $325.96

The current price is below all three moving averages, suggesting a potential downward trend. The short-term (5-day) moving average is closer to the current price than the longer-term averages, which could indicate some short-term support.

**3. Technical Indicators**

* **RSI:** 44.15 - This reading suggests that the stock is neither overbought nor oversold.
* **PPO:** -0.12 - This indicates a weak momentum in the stock's price.
* **Delta_Previous_Relative_Divergence:** -12.87 - This indicates a recent short-term downward trend in the relative performance of AMGN compared to the S&P 500.
* **Expected Return:** 0.0% - This indicates that, based on historical data, AMGN is not expected to outperform the S&P 500 significantly over the next 2 years with a long-term buy-and-hold strategy.

**4. Recent Earnings and Outlook**

| Date       | EPS      | Revenue     |
|------------|----------|-------------|
| 2024-08-07 | 1.39     | $8.39 B     |
| 2024-05-03 | -0.21    | $7.45 B     |
| 2023-10-31 | 3.23     | $6.90 B     |
| 2023-08-04 | 2.58     | $6.99 B     |
| 2024-08-07 | 2.58     | $6.99 B     |

The most recent earnings report for Q2 2024 showed a significant drop in EPS to $1.39, which was below analyst expectations. The revenue, however, exceeded expectations, indicating that AMGN's sales are holding strong despite the decline in profitability. The overall outlook for AMGN remains uncertain, as the company navigates a challenging market environment.

**5. News and Recent Issues**

**Recent Market Outlook:** The market outlook for AMGN remains mixed.  Some analysts are optimistic about the company's growth prospects, citing its strong position in the biopharmaceutical market and its pipeline of promising new drugs. Others are concerned about the company's high valuation and the potential for increased competition.

**Analyst Opinions:** Analyst opinions on AMGN are divided. Some analysts have recently downgraded their rating on the stock, citing concerns about the company's earnings growth. Others maintain a positive outlook, believing that the company's long-term growth prospects remain strong.

**Performance Highlights:**  
* AMGN is facing competition from biosimilar drugs for some of its key products.
* The company is investing heavily in research and development to maintain its leadership in the biopharmaceutical market.
* AMGN has a strong dividend history and is currently trading at a relatively low price-to-earnings ratio.

**6. Overall Analysis**

While AMGN is a strong company with a solid track record, its recent performance has been disappointing, with the stock underperforming the S&P 500. The recent earnings report highlights some challenges, including lower profitability and competition. 

While the stock is not currently overbought, the technical indicators suggest a possible downward trend in the short term. The expected return is modest, suggesting that investors might consider other investment options with higher potential for growth.

**7. Summary**

Based on the information available, AMGN presents a mixed investment proposition. While the company has a strong brand and presence in the biopharmaceutical market, recent performance and technical indicators suggest caution. Investors should carefully consider the company's challenges and opportunities before making an investment decision. 
